Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 1 country.
Iga StukanLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.ORCID 0000-0003-3560-6339
Marek GryzikLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.
Grażyna HoserLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.ORCID 0000-0002-0917-5611
Andrew WantLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.ORCID 0000-0001-7800-873X
Wioleta Grabowska-PyrzewiczLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.
Mikolaj ZdiorukLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.
Mariola NapiórkowskaDepartment of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-1174-2208
Marcin CieślakCentre of Molecular and Macromolecular Studies, Polish Academy of Sciences, 90-363 Lodz, Poland.ORCID 0000-0002-9628-214X
Karolina Królewska-GolińskaCentre of Molecular and Macromolecular Studies, Polish Academy of Sciences, 90-363 Lodz, Poland.ORCID 0000-0002-2979-8867
Barbara NawrotCentre of Molecular and Macromolecular Studies, Polish Academy of Sciences, 90-363 Lodz, Poland.ORCID 0000-0002-4084-4334
Grzegorz BasakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0003-3858-8180
Urszula WojdaLaboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.ORCID 0000-0002-4525-2004
Instytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLCentrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk · PLMedical University of Warsaw · PL
Funding
National Science Center OPUS8 2014/15/B/NZ7/00966
6 · The paper itself
Abstract
The search is ongoing for new anticancer therapeutics that would overcome resistance to chemotherapy. This includes chronic myeloid leukemia, particularly suitable for the studies of novel anticancer compounds due to its homogenous and well-known genetic background. Here we show anticancer efficacy of novel dicarboximide denoted BK124.1 (C
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients' CD34 · full record | OpenQuestion